Public company intelligence preview
BICYCLE THERAPEUTICS PLC
87 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $3.0M average total compensation across covered insiders.
Governance movement
Public aggregate: 4 governance events in the last year.
Institutional ownership
Public aggregate: 108 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
Bicycle Therapeutics plc is a Healthcare sector, Biotechnology industry company focused on developing proprietary Bicycle molecules for high-unmet-need diseases, especially oncology. It is still a clinical-stage biotech with no product sales, so its value is driven by clinical readouts, regulatory progress, and partnerships rather than commercial revenue. The company’s lead programs include nuzefatide pevedotin (BT5528), zelenectide pevedotin, BT1702, and BT7480, with recent management action shifting the portfolio toward next-generation therapeutics and away from some legacy internal programs.
Executive Compensation Practices
For a company like Bicycle Therapeutics, executive compensation is typically tied more to clinical, regulatory, and strategic milestones than to revenue growth or earnings, since the company is pre-commercial and currently operating at a loss. The filing indicates that share-based compensation is a meaningful cost, which is common in biotechnology and often aligns management pay with long-term equity value creation and trial success. Given the sharp changes in R&D spending, headcount reductions, and the portfolio reprioritization, compensation incentives are likely influenced by milestones such as trial enrollment, data readouts, partnering outcomes, cash runway management, and cost-reduction execution. In this sector, bonus metrics often emphasize pipeline advancement, capital discipline, and preservation of liquidity rather than traditional profitability measures.
Insider Trading Considerations
Insider trading patterns at Bicycle Therapeutics should be viewed in the context of a clinical-stage biotech with binary event risk: stock moves are often driven by trial results, FDA/EMA interactions, partnership updates, and portfolio decisions. Executives and directors may have blackout periods around major data releases, and trading activity may cluster around financing windows, clinical milestones, or strategic announcements like the recent reprioritization and workforce reduction. Because the company relies on equity financing and collaboration revenue, insiders may be especially sensitive to cash runway, dilution risk, and the timing of future capital raises. For researchers and traders, purchases after share-price weakness can sometimes signal confidence in upcoming data, while sales may reflect diversification or liquidity needs rather than a negative view, especially in a volatile biotech development cycle.
Unlock the full BCYC insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.